Nanolive announces an initial closing series C-1 round

Nanolive announces an initial closing series C-1 round

04.4.2022 – Nanolive SA, EPFL Startup and leading live cell imaging and analysis company, announces today that it has successfully completed the initial closing of US $20 million in the Series C-1 equity financing round of investment.

Nanolive’s cutting edge label-free microscope devices and state-of-the-art digital analytical solutions provide researchers and scientists working in the biopharmaceutical industry and laboratories with all the tools required to accelerate innovation in growth industries such as drug discovery and cell therapy.

Being able to screen thousands of living cells in 3D, without damaging them promises to radically advance how scientists study living cells. But the quantitative analytical suite Nanolive offers is a complete game-changer. Combining sub-cellular resolution with unique AI-assisted digital assays provide researchers and scientists a unique opportunity to study complex cell-drug perturbation dynamics and cell-cell interactions (e.g., T cell and target cell interactions), quantitatively, an approach that will revolutionize the cell-based assay phase of the drug discovery workflow.

An initial closing of Series C-1 round of US $20 million 

The initial closing of US $20 million in the Series C-1 equity financing round of investment is led by a US-based and NASDAQ listed life science investor, and Taiwania Capital, the leading life science venture capital company based in Taiwan.

This equity round of investment is also supported by investments from existing investors, including Swisscom Ventures, along with other partners. Nanolive is working closely with investors to secure a second close within ninety days.

Life Sciences are undergoing a fundamental transformation, and Nanolive is at the heart of it,” says Dr. Yann Cotte, Nanolive’s CEO and Co-Founder. With this fundraising, Yann believes that  Nanolive is well positioned to drive significant growth of their Digital Assay solutions and is at the leading edge of this global bioeconomy gold rush.

We are thrilled to be part of a Swiss-based innovative company that will revolutionize the drug discovery process,” said Michael L. Huang, Managing Partner of Taiwania Capital. “With this funding, Nanolive is well positioned to provide crucial tools and solutions to pharmaceutical and biotech companies, and research institutes for developing better therapies that would save millions of patient lives”.

Source: PR Nanolive

Picture: (c) Nanolive 2022